Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
